IDEXX Sales Rise 10% as Margin Outlook Slips: Rapid Earnings Reaction
IDEXX raised its 2026 earnings forecast, but it also trimmed its margin outlook. Here’s what is really behind the raise, and why testing demand isn’t the reason.
IDEXX Laboratories reported a 10% increase in third-quarter revenue to approximately $1.21 billion, driven by an 11% boost in recurring diagnostics sales to veterinarians. The stock surged about 16% in early trading on Monday. Testing demand is the primary driver, but the company lowered its profit forecast for 2026, with the earnings lift stemming from tax, interest costs, and buybacks.
The rise in VetLab consumables, which vets use to operate IDEXX's in-clinic analyzers, accounted for over half of the recurring gain, highlighting the razor-and-blade business model where each new analyzer generates years of test sales. Despite flat instrument revenue, IDEXX's focus on placements rather than the price paid for the equipment is more crucial.
The company raised its revenue range but lowered its operating margin outlook, leaving full-year operating profit close to the previous midpoint. The $0.25 increase in EPS forecast is attributed to a lower tax rate, reduced interest expense, and fewer shares outstanding. Although the margin cut signals the fourth quarter, the gains through the first nine months already surpass the new full-year target, indicating minimal improvement in the final quarter as IDEXX absorbs costs from its CoVet software acquisition.
Investors should closely monitor fourth-quarter operating margin against last year's performance, as the guidance suggests little to no change. Additionally, rapid assay products show a decline in testing volumes this quarter, but price alone has contributed to sales growth.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
